• 1. An approach towards the synthesis of novel fused nitrogen tricyclic heterocyclic scaffolds via GBB reaction?
  Sandip Gangadhar Balwe,Yeon Tae Jeong Org. Biomol. Chem., 2018,16, 1287-1296
• 2. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 3. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 4. An Assessment of the Laminar Hypersonic Double-Cone Experiments in the LENS-XX Tunnel
  JaideepRay,PatrickBlonigan,EricT.Phipps,KathrynMaupin
• 5. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis

• Pesticide Chemicals Pesticide Active Ingredients Standard Substances
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances
• Other Chemical Reagents

Metronidazole (CAS No. 443-48-1): A Comprehensive Overview of Its Applications and Recent Research Developments

Metronidazole, with the chemical formula C₆H₉N₃O, is a well-known antibiotic and antiprotozoal medication widely recognized for its efficacy in treating a variety of infections caused by anaerobic bacteria and certain protozoa. Its chemical structure, characterized by a nitroimidazole ring system, plays a crucial role in its mechanism of action, which involves the inhibition of bacterial DNA synthesis and disruption of protozoan energy metabolism. The compound was first synthesized in the 1950s and has since become a cornerstone in both clinical and research settings.

The primary therapeutic applications of Metronidazole include the treatment of infections such as bacterial vaginosis, trichomoniasis, amebic dysentery, and hepatic encephalopathy associated with bacterial overgrowth. Its broad-spectrum activity against anaerobic organisms makes it particularly valuable in clinical scenarios where these pathogens are implicated. The drug is available in various formulations, including oral tablets, intravenous solutions, and topical gels, allowing for diverse administration routes depending on the specific infection being treated.

In recent years, significant research has been conducted to explore the potential of Metronidazole beyond its traditional applications. One notable area of investigation has been its role in managing inflammatory conditions. Studies have demonstrated that Metronidazole exhibits anti-inflammatory properties by modulating the production of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6). This finding has opened up new avenues for its use in conditions like rheumatoid arthritis and inflammatory bowel disease, where conventional treatments may not be fully effective.

Another emerging field of research involves the use of Metronidazole in cancer therapy. Preliminary studies have suggested that Metronidazole can induce apoptosis in certain cancer cell lines by disrupting mitochondrial function and activating stress signaling pathways. Additionally, its ability to inhibit DNA topoisomerases has led to investigations into its potential as a chemosensitizer when used in conjunction with other chemotherapeutic agents. These findings are particularly promising for the development of novel combination therapies that could enhance treatment outcomes for patients with solid tumors and hematological malignancies.

The pharmacokinetics of Metronidazole are also subjects of ongoing research. The drug is rapidly absorbed after oral administration and is metabolized primarily in the liver through enzymatic processes involving cytochrome P450 enzymes. Recent studies have focused on identifying genetic polymorphisms that influence Metronidazole metabolism, which could help predict individual responses to therapy and optimize dosing regimens. This personalized medicine approach holds great potential for improving patient outcomes and reducing the risk of adverse effects.

In addition to its pharmacological applications, Metronidazole has found utility in veterinary medicine. It is commonly used to treat infections caused by anaerobic bacteria and protozoa in animals, including dogs, cats, and livestock. Its broad-spectrum activity makes it a valuable tool for managing infections such as periodontal disease, abscesses, and systemic infections in veterinary patients. The development of veterinary formulations has expanded the scope of Metronidazole's use, contributing to better health outcomes for animals.

The safety profile of Metronidazole is well-documented, but like all medications, it is associated with potential side effects. Common adverse reactions include nausea, vomiting, diarrhea, and metallic taste sensations. More serious side effects, although rare, can include neurological symptoms such as headache, dizziness, and peripheral neuropathy. It is important to note that Metronidazole can also cause severe reactions when taken with certain alcohol-containing beverages or medications containing propylene glycol. Therefore, patients are advised to avoid these substances while undergoing Metronidazole therapy to prevent adverse interactions.

The regulatory status of Metronidazole varies by country but is generally well-established due to its long history of use and proven efficacy. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved Metronidazole for various indications based on extensive clinical data supporting its safety and effectiveness. Ongoing surveillance programs monitor for new safety concerns or emerging resistance patterns to ensure that Metronidazole remains a reliable therapeutic option.

The future directions for research on Metronidazole are multifaceted. One area involves exploring its potential role in antimicrobial resistance management. As bacteria continue to develop resistance to conventional antibiotics, there is growing interest in repurposing existing drugs like Metronidazole to combat resistant strains. Additionally, researchers are investigating novel derivatives of Metronidazole that may enhance its efficacy while reducing side effects.

In conclusion, Metronidazole, with the CAS number 443-48-1, remains a vital medication in modern medicine with diverse applications ranging from infectious diseases to inflammatory conditions and cancer therapy. Its unique chemical properties enable it to interact with microbial pathogens in ways that conventional antibiotics cannot match. As research continues to uncover new therapeutic uses for this compound, it is likely that Metronidazole will continue to play an important role in healthcare for years to come.

• 1077-93-6(2-Methyl-5-nitroimidazole-1-propanol)
• 16156-94-8(O-Hydroxyethyl Metronidazole)
• 70028-95-4(Ternidazole Hydrochloride)
• 62580-80-7(3-Deschloro-3-hydroxy Ornidazole)
• 110321-22-7(Platinum,amminedichloro(2-methyl-5-nitro-1H-imidazole-1-ethanol-N3)-, (SP-4-3)- (9CI))
• 1215071-08-1(Hydroxy Metronidazole-d4)
• 3366-95-8(secnidazole)
• 4812-40-2(Hydroxy Metronidazole)
• 69198-10-3(1H-Imidazole-1-ethanol,2-methyl-5-nitro-, hydrochloride (1:1))
• 84151-71-3(Platinum,dichlorobis(2-methyl-5-nitro-1H-imidazole-1-ethanol-kN3)-, (SP-4-2)-)